The DOI matches its Crossref record.
Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein
Abstract
OBJECTIVE: Recent data indicated that disposition of oral digoxin is modulated by intestinal P-glycoprotein. The cardioselective beta-blocker talinolol has been described to be secreted by way of P-glycoprotein into the lumen of the gastrointestinal tract after oral and intravenous administration. We therefore hypothesized that coadministration of digoxin and talinolol may lead to a drug-drug interaction based on a competition for intestinal P-glycoprotein. METHODS: Pharmacokinetics of digoxin (0.5 mg orally), talinolol (30 mg intravenously and 100 mg orally), and digoxin plus talinolol orally, as well as digoxin plus talinolol intravenously, were assessed in five male and five female healthy volunteers (age range, 23 to 30 years; body weight, 60 to 95 kg) in a changeover study with at least a 7-day washout period. Digoxin and talinolol were analyzed by fluorescence polarization immunoassay and HPLC, respectively. RESULTS: Oral coadministration of 100 mg talinolol increased the area under the concentration-time curve (AUC) from 0 to 6 hours and the AUC from 0 to 72 hours of digoxin significantly by 18% and 23%, respectively (5.85+/-1.49 versus 7.22+/-1.29 ng x h/mL and 23.0+/-3.3 versus 27.1+/-3.7 ng x h/mL, for both P<.05) and the maximum serum levels by 45%. Renal clearance and half-life of digoxin remained unchanged. Coinfusion of 30 mg talinolol with oral digoxin had no significant effects on digoxin pharmacokinetics. Digoxin did not affect the disposition of talinolol after both oral and intravenous administration. CONCLUSION: We observed a significantly increased bioavailability of digoxin with oral coadministration of talinolol, which is most likely caused by competition for intestinal P-glycoprotein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.815 · Cited by 792
The Gut as a Barrier to Drug Absorption: Combined Role of Cytochrome P450 3A and P-Glycoprotein
Zhang, Y., & Benet, L. Z. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00002 · Cited by 518
Transporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
Impact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Butler, J. M., & Dressman, J. B. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22217 · Cited by 427
Role of transport proteins in drug absorption, distribution and excretion
Ayrton, A., & Morgan, P. (2001) · Xenobiotica · doi:10.1080/00498250110060969 · Cited by 421
Fluorescence polarization assays in small molecule screening
Lea, W. A., & Simeonov, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.537322 · Cited by 379
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
Expression and function of efflux drug transporters in the intestine
Takano, M., Yumoto, R., & Murakami, T. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.005 · Cited by 356
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Cascorbi, I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.009 · Cited by 355
Vogelgesang, S., Cascorbi, I., Schroeder, E., Pahnke, J., Kroemer, H. K., Siegmund, W., Kunert-Keil, C., Walker, L. C., & Warzok, R. W. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00005 · Cited by 345
Prediction of intestinal permeability
Egan, W. J., & Lauri, G. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00004-2 · Cited by 344
Intestinal drug transporters: An overview
Estudante, M., Morais, J. G., Soveral, G., & Benet, L. Z. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.042 · Cited by 330
The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective
Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., et al. (2003) · Journal of Clinical Pharmacology · doi:10.1177/0091270003043005001 · Cited by 315
Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo
Cornaire, G., Woodley, J., Hermann, P., Cloarec, A., Arellano, C., & Houin, G. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.03.001 · Cited by 307
Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284
Fenner, K., Troutman, M., Kempshall, S., Cook, J., Ware, J., Smith, D., & Lee, C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.195 · Cited by 272
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics
Boulton, D. W., DeVane, C. L., Liston, H. L., & Markowitz, J. S. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)01680-6 · Cited by 259
Metadata
- Authors
- Westphal, K.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2000-07
- Volume
- 68
- Issue
- 1
- Pages
- 6-12
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2076491064
- Cited by
- 177
- References
- 0
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.